Introduction
Cervical cancer is an invasive cancer of the uterine cervix. It spreads either by direct extension, growing to involve the uterus, vagina, parametria (tissue just lateral to the cervix and uterus) and/or the pelvic side walls or through the lymphatic and less often vascular system.
Cervical cancer is the 3 rd most common gynecologic malignancy and the 6 th most common solid malignant neoplasm among women in the United States (US). In 2010, approximately 12,200 cases were diagnosed in the US with 4,210 deaths. 1 However; worldwide, cervical cancer is the 2 nd most common cause of all cancer related deaths in women. In 2002, ~500,000 new cases were diagnosed in developing countries and there were ~ 275,000 deaths observed, corresponding to a ~50% mortality rate. This chapter provides an overview of cervical cancer. The etiology, pathology, staging, and principles of treatment will be reviewed.
Screening and Pre-Invasive Disease
The cervical cytology known as Pap smear is a first screening tool that detects cervical precancerous changes. Treatment of these changes prevents progression to invasive or advanced stage of the disease. The Pap smear was named after George Papanicolaou, who developed it in the 1940's. It was widely implemented in 1950's in the USA. It works by evaluating scrapings of cervical cells under a microscope. This microscopic evaluation allows the pathologist to categorize cells as either normal or with varying degrees of precancerous changes ( Figure 1 ). Figure 1 . The Pap test is designed to sample only cells at the surface of the epithelium. In this image, there are several normal mature squamous cells (pink or blue depending on the presence of particular keratins-a feature that has no importance for students at this level). An arrow points to a
The word "precancerous" has acquired a large number of synonyms.
In part the large number of similar terms reflects medical-legal pressure to avoid implying that precancerous changes inevitably progress to invasive cancer. Synonyms include "pre-invasive", "dysplastic", "cervical intraepithelial neoplasia" (a term used to define histologic features in biopsies), or "squamous intraepithelial lesion" (a term used to define the cellular-level features seen in Pap smears
Cervical cancer was one of the first human cancers to illustrate the now generally accepted concept that there is a step-wise progression from normal cells, to dysplastic cells, and finally to invasive disease.
Cervical intraepithelial neoplasia (CIN) refers to pre-invasive dysplasia of cervical epithelial cells. It is the antecedent of malignant disease. CIN is categorized primarily according to the extent to which squamous cells fail to mature as they migrate from the basal zone next to the basement membrane to the surface of epithelium. In CIN I, (also known as "mild dysplasia") cells begin to "mature" within the lower third of the epithelium ( Figure 2 ). thereby spreading virus. Normal squamous epithelium, under the influence of physiologic amounts of estrogen, accumulates glycogen as cell mature upward away from the basal layer. Glycogen is extracted in tissue processing and therefore also appears as a white-colored area around the nucleus in the maturing squamous cells. Compared to CIN 1, the normal glycogenated clear zone around the nuclei is more regular, giving rise to a "basket-weave" pattern, whereas the HPV infected cells show a disordered basket weave pattern. In CIN 1, multiple rounds of unscheduled DNA synthesis induced by HPV E6 and E7 genes cause exponential production of viral genomes. The unscheduled DNA synthesis also causes the nuclei to acquire polyploid amounts of DNA (2, 4, 8 In CIN II (also known as "moderate" dysplasia), cells begin to mature in the middle third of the epithelium (Figure 3 ). In CIN III (also known as "severe dysplasia" or "squamous cell carcinoma in situ") cells do not mature until the upper third of the epithelium (Figure 4 ). In Pap testing, a "low-grade squamous intraepithelial lesion" is synonymous with CIN I, whereas a "high grade squamous intraepithelial lesion" is synonymous with CIN II or CIN III ( Figure 5 & Figure 6 ). Figure 3 . This is a different cervical biopsy stained for Ki67 antigen, an antigen expressed in cells that have retained replication competence. The location of Ki67 staining cells is indicated by the brown color. The surface of the epithelium is toward the top and arrowheads show the location of the basal layer of the epithelium. In this biopsy, there is CIN 2 on the left half of the image, and normal squamous epithelium on the right half. Note that there is an increase in the thickness of the zone in which replication competence is maintained in the CIN 2. In CIN 2, replication competence is maintained for about half of the thickness of the epithelium. University of Massachusetts Medical School Department of Pathology. Figure 4 . A cervical biopsy is shown with CIN III, also known as "severe dysplasia". Short arrows point to the location of the basal aspect of the epithelium; the underlying stromal tissue has been ripped away artifactually. Note the lack of change of the appearance of the cells as they grow away from the basal zone: it is as if the cells retained basal-like features, or lost the ability to differentiate as they reach the surface. Note also the mitotic cell that is approximately 2/3 of the way from the basal area to the surface (long thin arrow). University of Massachusetts Medical School Department of Pathology. Figure 5 . A Pap test cytology sample is shown with a high grade squamous intraepithelial lesion, corresponding to a cervical biopsy with CIN III. A diagnostic feature of high grade dysplasia is the cell to cell variation in total amount of hematoxylin, corresponding to a cell by cell variation in total DNA content. In other words, there is "genetic instability" characterized by frequent gains and losses of chromosomes at each cell division. As an internal control for normal DNA content, look at the normal squamous cells (the two cells with the most cytoplasm) and compare their DNA content to the cluster of dysplastic squamous cells toward the left. High grade dysplastic cells do not acquire much cytoplasm, so the "nuclear to cytoplasmic ratio" is much higher (about 1:1.5) compared to the normal squamous cell (with an N:C ratio of about 1:7). University of Massachusetts Medical School Department of Pathology. 
Etiology and Risk Factors
The human papilloma virus (HPV) is known to be the major etiologic factor in development of cervical dysplasia and cancer. And it was recognized to be caused by specific HPV types. HPV is a sexually transmitted infection. There are many different strains of this virus that can infect the cervix, but only about 15 strains are associated with risk of cancer. Testing directly for these "high risk" HPV types is playing an increasingly large role in screening for cervical cancer, 
Pathology
Most cervical cancers arise from the transformation zone of the cervix where the squamous and columnar cells join, often referred to as the squamo-columnar junction (Figure 8 ). 
Symptoms and Signs
Cervical neoplasia has no symptoms until it becomes invasive in which time abnormal vaginal discharge that is unresponsive to treatment, post coital bleeding, irregular and out of phase menstrual bleeding and in advanced stage pelvic pain occur. The signs of invasive cervical cancer include an irregular firm feeling of the cervix.
A knobby feeling can sometimes be appreciated when using a spatula to sample the cervix for a pap test. The cervical ulceration is seen in some cases on cervical inspection ( Figure 10 ). 
Principles of Treatment
Pre-invasive disease is generally treated with expectant management (lower grades of dysplasia) or removal of precursor lesions by LEEP, CKC, ablation or cryotherapy.
Most cervical cancers that have not spread beyond the cervix are potentially cured with current treatments. However, once these cancers have spread into distant sites, such as lungs, bone, or liver, they are incurable and treatment is largely palliative.
In general, early stage cervical cancers are treated with surgery.
More advanced stages of cervical cancer are generally treated with radiation and concurrent chemotherapy. pelvis or pelvic side walls, and hopefully shrinks the central tumor, so that the brachytherapy, which follows, can be more effective, by improving the anatomic geometry of the implant. Brachytherapy (i.e., "short distance" or localized and not external beam) radiation therapy with intracavitary radium or cesium or interstitial cesium needles is used to treat central tumor sites.
In young women of childbearing age with an early stage 1B-2 cervical cancer, radical resection of the cervix and pelvic lymph node dissection with preservation of the uterine fundus for future pregnancy has been accepted as a method of treatment.
Stage IVB cervical cancer has a poor prognosis and is generally treated with the ultimate goal of palliation.
With the completion of definitive therapy, each patient is evaluated with physical examinations and pap smears. They are generally evaluated every 3 months for 1-2 years, every 6 months until the 5 th
year and yearly thereafter.
Cervical Cancer Prevention
HPV vaccination has been developed to prevent women from developing intraepithelial neoplasia and cancer. This vaccination is against HPV 16-18 strains and is indicated for girls ages 9-26. . Figure Tumor "Grade"-Refers to the pathologist's impression of how aggressive the tumor will behave. Grading for most cancers takes into account the following three features: 1) How closely do the cells resemble the cell of origin of the tumor? The degree to which tumor cells resemble the structure of normal tissue is referred to as "differentiation". Intuitively, one can imagine that a "poorly differentiated" tumor (in which cells have lost much of the genetic programming of their origin), has evolved more, and is more likely to be able to adapt to new environments. For breast cancer, the degree of differentiation is estimated based on how well the cells can still cooperate to form tubular structures. For extremely well-differentiated "tubular carcinomas" of the breast, the risk of metastasis is close to zero. 2) How genetically unstable are the tumor cells? This is estimated from how much variability or "pleomorphism" is shown by the cells. The importance of pleomorphism can be understood intuitively: A highly genetically unstable, pleomorphic tumor is more likely to be able to evolve and adapt to new environments. 3-How fast is the tumor growing? Obviously a faster growing tumor may show a faster clinical evolution. Growth rate can be estimated based on the percentage of tumor cells that are in mitosis. More quantitative methods for estimating the growth rate can be achieved by immunohistochemical staining for proliferation markers. For example Ki67 immunostaining will highlight cells in S, M and G2 of the cell cycle. Image analysis of Ki67 staining shows promise for achieving more precise proliferation quantification. For certain tumors, there are other features that are important for "grade". These include the presence of necrosis (particularly important for grading tumors of mesenchymal origin-i.e., sarcomas) and nucleolar size (particularly important for grading renal cell carcinomas).
Conclusion

